Emerging insights into the biology and therapy of malignant mesothelioma

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 18, 2002, Pages 35-42

  Vogelzang, Nicholas J ^a  

^a University of Chicago   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FOLIC ACID; GEFITINIB; GEMCITABINE; HOMOCYSTEINE; IMATINIB; INTERLEUKIN 2; METHOTREXATE; METHYLMALONIC ACID; MITOMYCIN C; NAVELBINE; PEMETREXED; PLATELET DERIVED GROWTH FACTOR; SEMAXANIB; THALIDOMIDE; TRIMETREXATE; VASCULOTROPIN; VATALANIB; VINBLASTINE;

AGE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CYANOCOBALAMIN DEFICIENCY; FOLIC ACID DEFICIENCY; HISTOPATHOLOGY; HUMAN; MALIGNANT MESOTHELIOMA; NEUTROPENIA; PERITONEUM MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIMIAN VIRUS 40; STOMATITIS; SURVIVAL RATE; VITAMIN SUPPLEMENTATION;

EID: 0036987136     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.37469     Document Type: Review

References (51)

1. Carbone M, Kratzke RA, Testa JR: The pathogenesis of mesothelioma. Semin Oncol 29:2-17, 2002
2. Peto J, Decarli A, La Vecchia C, et al: The European mesothelioma epidemic. Br J Cancer 79:666-672, 1999
3. Price B: Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 145:9-16, 1997
4. Cicala C, Pompetti F, Carbone M: SV-40 induces mesotheliomas in hamsters. Am J Pathol 142:1524-1533, 1993
5. Testa JR, Carbone M, Hirvonen A, et al: A multi-institutional study confirms the presence and expression of Simian Virus 40 in human malignant mesotheliomas. Cancer Res 58:4505-4509, 1998
6. Bocchetta M, Di Resta I, Powers A, et al: Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci U S A 97:10214-10219, 2000
7. Bookchin D, Schumacher J: The virus and the vaccine. Atlantic Monthly, February 2000 Available at: http://www. theatlantic.com/issues/2001/02/index.htm (part one); http://www.theatlantic.com/issues/2000/02/002bookchin2.htm (part two); and http://www.theatlantic.com/issues/2000/02/002bookchin3.htm (part three)
8. Baris YI, Sahin AA, Ozesmi M, et al: An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/Urgup in Anatolia. Thorax 33:181-192, 1978
9. Roushdy-Hammady I, Siegel J, Emri S, et al: Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 357:444-445, 2001
10. Vogelzang NJ, Schultz SM, Iannuci AM, et al: Malignant mesothelioma: The University of Minnesota experience. Cancer 53:377-383, 1984
11. Herndon JE, Green MR, Chahinian AP, et al: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113:723-731, 1998
12. Strizzi L, Catalano A, Vianale G, et al: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193:468-475, 2001
13. Curran D, Sahmoud T, Therasse P, et al: Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16:145-152, 1998
14. Rusch VW, Venkatraman ES: Important prognostic factors in patients with malignant pleural mesothelioma. Ann Thoracic Surg 68:1799-1804, 1999
15. Edwards JG, Abrams KR, Leverment JN, et al: Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems. Thorax 55:731-735, 2000
16. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al: Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 20:274-281, 2001
17. Kindler HL: Malignant pleural mesothelioma. Curr Treat Options Oncol 1:313-326, 2000
18. Grondin SC, Sugarbaker DJ: Pleuropneumonectomy in the treatment of malignant pleural mesothelioma. Chest 116: 450S-454S, 1999
19. Rusch VW, Rosenzweig K, Venkatraman E, et al: A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122:788-795, 2001
20. Ong ST, Vogelzang NJ: Chemotherapy in malignant pleural mesothelioma: A review. J Clin Oncol 14:1007-1017, 1996
21. Astoul P, Picat-Joosen D, Viallat JR, et al: Intrapleural administration of interleukin 2 for the treatment of patients with malignant pleural mesothelioma: A phase II study. Cancer. 83:2099-2104, 1999
22. Mintzer DM, Kelsen D, Frimmer D, et al: Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 69:711-712, 1985
23. Zidar BL, Green S, Pierce HI, et al: A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group study. Invest New Drugs 6:223-226, 1988
24. Planting AST, Schellens JHM, Goey SH, et al: Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann Oncol 5:373-374, 1994
25. Middleton GW, Smith IE, O'Brien ME, et al: Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 9:269-273, 1998
26. Steele JP, Shamash J, Evans MT, et al: Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18:3912-3917, 2000
27. Girling DJ, Muers MF, Qian W, et al: Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council. Semin Oncol 29:98-101, 2002
28. Kindler HL, van Meerbeeck JP: The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol 29:70-76, 2002
29. Kindler HL, Millard F, Herndon JE II, et al: Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 31:311-317, 2001
30. van Meerbeeck JP, Baas P, Debruyne C, et al: A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research Treatment of Lung Cancer Cooperative Group. Cancer 85:2577-2582, 1999
31. Bischoff HG, Manegold C, Knopp M, et al: Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 17:464a, 1998 (abstr 1784)
32. Byrne MJ, Davidson JA, Musk AW, et al: Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 17:25-30, 1999
33. van Haarst JM, Baas P, Manegold C, et al: Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86:342-345, 2002
34. Aversa SML, Favaretto AG: Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: A phase II study of the GSTPV. Clin Lung Cancer 1:1, 1999
35. Nowak A, Byrne M, Williamson R, et al: Multicentre phase II study of cisplatin (C) and gemcitabine (G) in malignant mesothelioma (MM). Ann Oncol 11:109, 2000 (suppl 4) (abstr)
36. Taylor EC, Kuhnt D, Shih C, et al: A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)- ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35:4450-4454, 1992
37. Thödtmann R, Depenbrock H, Dumez H, et al: Clinical and pharmacokinetic phase I study of multi-targeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 17: 3009-3016, 1999
38. Calvert AH, Hughes AN, Calvert PM, et al: Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial. Lung Cancer 29:73, 2000 (suppl 2)
39. Vogelzang NJ, Goutsou M, Corson JM, et al: Carboplatin in malignant mesothelioma. A phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 27:239-242, 1990
40. Raghavan D, Gianoutsos P, Bishop J, et al: Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 8:151-154, 1990
41. Mbidde EK, Harland SJ, Calvert AH, et al: Phase II trial of carboplatin (JM8) in the treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 18:284-285, 1986
42. Niyikiza C, Baker SD, Seitz DE, et al: Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1:545-552, 2002
43. Bunn P, Paoletti P, Niyikiza C, et al: Vitamin B12 and folate reduce toxicity of ALIMTA (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol 20:76a, 2001 (abstr 300)
44. Shin DM, Scagliotti G, Kindler H, et al: A phase II trial of pemetrexed in malignant pleural mesothelioma (MPM) patients: Clinical outcome, role of vitamin supplementation, respiratory symptoms and lung function. Proc Am Soc Clin Oncol 21:294a, 2002 (abstr 1175)
45. Vogelzang NJ, Rusthoven J, Paoletti P, et al: Phase III single-blinded study of pemetrexed + cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma. Proc Am Soc Clin Oncol 21:2a, 2002 (abstr 5)
46. Fizazi K, John WJ, Vogelzang NJ: The emerging role of antifolates in the treatment of malignant pleural mesothelioma. Semin Oncol 29:77-81, 2002 (suppl 1)
47. Kindler HL: Systemic Therapy for Malignant Mesothelioma, in American Society of Clinical Oncology Educational Book, Spring 2002, Alexandria, VA, pp 359-367
48. Kindler HL, Vogelzang NJ, Chien K, et al: SU5416 in malignant mesothelioma: A University of Chicago Phase II Consortium Study. Proc Am Soc Clin Oncol 20:341a, 2001 (abstr 1359)
49. Eisen T: Thalidomide in solid malignancies. J Clin Oncol 20:2607-2609, 2002
50. Wood JM, Bold G, Buchdunger E, et al: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor receptor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189, 2000
51. Nowak AK, Lake RA, Kindler HL, et al: New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 82-96, 2002 (suppl 1)